Multicentric Standardization of Protocols for the Diagnosis of Human Mitochondrial Respiratory Chain Defects

Nuria Bujan 1,†,‡, Constanza Morén 2,†,‡, Francesc J. García-García 2,†,‡, Alberto Blázquez 3,†, Elena García-Arumí 4,†, Ana Belén Cortés 5,†, Cristina González 6,†, Ester López-Gallardo 7,†, Estefanía Lozano 8, Sonia Moliner 1,†, Laura Gort 1,†,‡, Ester Tobias 2,†, Aitor Delmiro 3,†, Miguel Ángel Martín 3,†, Miguel Ángel Fernández-Moreno 6,†, Eduardo Ruiz-Pesini 7,†, Elena García-Arumí 9,†, Juan Carlos Rodríguez-Aguilera 5,*,‡ and Glòria Garrabou 2,†,‡,*.

Abstract: The quantification of mitochondrial respiratory chain (MRC) enzymatic activities is essential for diagnosis of a wide range of mitochondrial diseases, ranging from inherited defects to secondary dysfunctions. MRC lesion is frequently linked to extended cell damage through the generation of proton leak or oxidative stress, threatening organ viability and patient health. However, the intrinsic challenge of a methodological setup and the high variability in measuring MRC enzymatic activities represents a major obstacle for comparative analysis amongst institutions. To improve experimental and statistical robustness, seven Spanish centers with extensive experience in mitochondrial research and diagnosis joined to standardize common protocols for spectrophotometric MRC enzymatic measurements using minimum amounts of sample. Herein, we present the detailed protocols, reference ranges, tips and troubleshooting methods for experimental and analytical setups in different sample preparations and tissues that will allow an international standardization of common protocols for the diagnosis of MRC defects. Methodological standardization is a crucial step to obtain comparable reference ranges and international standards for laboratory assays to set the path for further diagnosis and research in the field of mitochondrial diseases.

Keywords: mitochondrial respiratory chain; enzyme activity; standardization; diagnosis; mitochondrial disease
1. Introduction

Mitochondria are responsible for powering cell metabolism, calcium homeostasis and heat production. However, under pathologic conditions, mitochondria are also sources for reactive oxygen species (ROS) and cell death [1,2]. Therefore, impaired mitochondrial function may lead the affected cell, tissue or patient to disease or even death [3,4]. Mitochondrial diseases include both inherited defects and secondary dysfunctions associated with physiologic aging or pathologic conditions, ranging from neurodegenerative to oncologic diseases. They constitute a remarkable diagnostic and research challenge because of their significant heterogeneity in clinical symptoms and the wide range of enzymatic reactions, coenzymes and transporters involved in energy metabolism. Additionally, two different genomes (nuclear and mitochondrial DNA) contain the different genes (approximately 1500 and 37, respectively), all coding for mitochondrial proteins. For every patient or disease, a definite diagnosis requires the identification of the responsible gene associated with a specific biochemical, pathological and clinical profile, which comprises diagnosis that requires the interdisciplinary cooperation of clinicians, pathologists, biochemists and geneticists [5]. In research, the specific identification of the dysfunctional mitochondrial defect is also usually hard to establish. Thus, frequently, the results are not easy to interpret due to tissue-specific genetic or biochemical defects that, in case of MRC, encompass the abnormal organization of MRC complexes and super-complexes, their high molecular size and associated instability.

Therefore, since mitochondrial dysfunction underlies numerous disorders, mitochondrial functional assays are often implemented in clinical and research settings to assess mitochondrial involvement in a physiologic or pathological condition. These assays can be performed in a multitude of biological samples and may include a wide range of parameters such as the quantification of ATP or ROS production [6,7], oxygen consumption [8], membrane polarization [9], oxidative phosphorylation coupling [10] or the assessment of protein folding into mitochondrial supercomplexes by blue native polyacrylamide gel electrophoresis [11], among others. However, in the clinical setting where sensitivity, specificity, precision, reproducibility and linearity are required, the determination of MRC enzyme activities is still the gold standard to assess mitochondrial dysfunction and its contribution to disease.

In humans, MRC is formed by four enzymatic complexes (I-IV) and two mobile electron transporters (coenzyme Q and cytochrome C), driving the electrochemical gradient and proton-motive force for energy production through ATP-proton synthase (complex V). The MRC function can be measured in tissue homogenates, cells or mitochondria-enriched fractions, and the obtained results must be compared to specific reference ranges. MRC analyses are routinely performed in energetic tissues with significant oxidative metabolism, mainly in skeletal muscle, although alternative measurements in less invasive samples such as fibroblasts or peripheral blood mononuclear cells (PBMC) are also measured in clinical settings [12]. Alternatively, the use of mitochondria-enriched fractions requires fresh tissue in significant amounts, and there may be a bias for the positive selection of healthy mitochondria from the global mitochondrial population due to differences in mitochondrial weight [13]. Consequently, in the context of clinical diagnosis, muscle tissue homogenate is the sample of choice for mitochondrial disease evaluation. In research settings, tissue and sample preparation frequently depend on the design, objective and model of study.

Sample collection, tissue homogenization, freezing and storage methods are essential steps for the stability of the mitochondrial enzymes and may vary depending on the centers. Additionally, the spectrophotometric methodologies used for protein quantification and MRC enzyme determinations are very diverse. Differences in several key aspects have been found among different laboratories [14]. In particular, in the experimental conditions used to make the sample accessible to reagents (through detergents solubility, osmotic shock or freezing-and-thawing cycles), the composition and pH of the reaction media, the presence or concentration of substrates and inhibitors, the temperature of measurement and the analytical procedure (specially the time of analysis) are usually different in each
laboratory [14]. These methodological differences may hamper result comparisons, the establishment of reference ranges or pathological thresholds and sample reanalysis in other specialized laboratories for a second opinion. Due to these difficulties, several authors have carried out inter-laboratory comparisons [14–16], concluding, in all cases, that a strict methodological standardization is necessary to improve the assessment of mitochondrial dysfunction.

In this context, seven Spanish laboratories belonging to the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), working in the diagnostic and research of mitochondrial diseases, started a coordinated program to establish common protocols for MRC enzyme determinations in all laboratories. The present work summarizes this experience and the reference values and adapted protocols to validate and standardize MRC assessment in mitochondrial diagnosis or research, with specific tips for the implementation of these protocols in other laboratories. The methods of this network for the standardization of MRC enzyme measurements were initially based on the protocols of French laboratories [15] to widen the scope of institutions implementing the same methodology, although individual contribution to protocol setup performed by the Italian group of Spinazzi et al., as well as in-house modifications, had been implemented to improve assay performance [16]. In this manuscript, differences in reagents and procedure setup with respect to the previous literature are highlighted, in addition to main troubleshooting assistance. Furthermore, detailed protocols for the implementation of all specific MRC assays are provided within Supporting information in Supplementary Materials.

MRC complex activities were measured spectrophotometrically and were expressed either as absolute (units), specific enzymatic activities (nmol·min⁻¹·mg of protein⁻¹) or normalized to citrate synthase (CS) activity, which is a widely considered biomarker of mitochondrial content [17–19]. Herein, we aimed to standardize MRC assays in the seven participant laboratories in which our results would be comparable, combining our experimental experience to overcome methodological pitfalls.

2. Materials and Methods

Extensive detailed protocols can be found in Supporting information in Supplementary Materials, and the main differences between proposed methodology and previous French protocols [15] are summarized in Table 1, together with troubleshooting solutions for critical methodological steps to improve result robustness.

2.1. Reagents

We used the reagents previously recommended for the MRC assay [15], except for decylubiquinol preparation, because this electron donor for complex III assay is extremely sensible to auto-oxidation, and in our hands, the reduction in decylubiquinol with dithionite (previously suggested) led to non-reproducible results. Thus, decylubiquinol preparation was performed by using sodium borohydride [20], which leads to a faster decylubiquinone reduction, requires lower amounts of reagent, prevents the contamination of decylubiquinol with traces of the chemical reducer and extends the stability of the resulting product from 2 h to 3 months (see reagents section in Supporting information).

2.2. Procedure

The protocols for MRC measurement were divided into the following: (i) sample collection; (ii) sample preparation (tissue homogenization, cell lysate and mitochondria-enriched preparation); (iii) protein measurement; (iv) MRC enzyme assessments; (v) CS quantification; and (vi) online database setup and result analyses (Figure 1).

As in the Reagents section, only differences with previous procedures have been highlighted [15], although detailed protocols can be found in Supporting information in Supplementary Materials.

(i) Sample collection (expected time: 15 min)
Human sample collection was carried out after written informed consent signature and ethics committee approval were obtained from each institution (C0000128, HCB2017/0808, CEI:18/487, PR(IR)63/2016 and C.I. 2768-N-21). Briefly, muscle, fibroblasts and PBMC samples were obtained for diagnostic purposes following standard medical procedures. These samples were obtained from subjects with clinical suspicion of a potential mitochondrial disease, and the results were used as normality ranges once the mitochondrial defect was ruled out.

Muscle samples were obtained from a biopsy of skeletal muscle (quadriceps, biceps or deltoids) and immediately frozen at $-80 \pm 5 \degree C$ until analysis. The characteristics of the individuals included in this study are summarized in Supplementary Table S1. Samples contaminated with biological fluids such as blood were cleaned by quick paper-tissue...
absorption (in case of tissue handling) or washed and centrifuged (in the case of cell management). Freezing the sample enables sample transport (from the hospital to the laboratory), sample storage (from collection to analysis) and mitochondrial membrane disruption (enabling substrates to access to the MRC). For muscle samples, a minimum of 50 mg of tissue is required to analyze all MRC activities. Additionally, for each included muscle biopsy, genetic and pathological analyses are performed in parallel to confirm the source of disease and the validity of the sample collected.

For isolated cell measurements (fibroblasts or PBMCs), a collection of a minimum of 5 million cells is recommended. Fibroblasts (collected from a skin punch biopsy and grown in standard culture media) and PBMC (collected in EDTA-plasma tubes and isolated by Ficoll density gradient centrifugation) were washed twice with PBS and frozen at $-80 \pm 5 \, ^\circ C$. For the quantification of MRC in mitochondrial-enriched preparations, fresh tissue or alive cells must be processed before cryopreservation.

(ii) Tissue homogenization, cell lysate and mitochondria-enriched preparation (expected time: 15 min–1 h)

Sample preparation is a critical step to obtain reproducible measurements. Tissue homogenate can be obtained by grinding or by using a polytron device in fresh or frozen tissue.

Frozen muscle samples were quickly thawed on ice-cold mannitol (50 mg of tissue in 200 µL) followed by immediate fragmentation into small pieces using scissors and subsequent homogenization. Although glass–glass homogenizers had been previously recommended [15], in our hands, preparations resulted in suboptimal enzymatic measurements. Consequently, we tested Teflon–glass potters that, in our experience, generated more consistent results. For reproducible results, we recommend keeping tissue and media on ice and handling pestles and mortars with perfect fitting [16]. Homogenization should be performed smoothly, avoiding shearing forces, with the same number of strokes (3–10 strokes), at 850 rpm of speed, alternating fast and slow strokes and using the minimal time needed to obtain homogeneous sample suspensions.

For fibroblasts or PBMC, cells were thawed using 150 µL of ice-cold mannitol media for 5 million cells and then slightly sonicated on ice (twice for 5 s at 200 Watts). Cryopreservation is an optional step from collection to sonication. Both procedures (cryopreservation and sonication) enable the release of MRC complexes to allow proper enzymatic measurements [16].

Mitochondria-enriched fractions from tissues or cells were obtained from fresh biological material (never frozen) through homogenization and sequential centrifugations [13,16,19].

(iii) Protein measurement (expected time: 1 h)

Immediately after sample preparation and before MRC measurements, it is recommended to proceed with protein measurement and subsequent sample dilution to a final concentration of 2 mg/mL in mannitol solution to standardize reaction conditions (sample and solution volumes) and to meet the optimal kinetic requirements for MRC enzyme assays.

Although both Lowry and bicinchoninic acid (BCA) protein assays are frequently used [15], in our hands, the Lowry method was not optimal due to interferences with the mannitol solution. Thus, for precise protein quantification, we used the BCA method run in 96-well microplates by measuring two sample dilution replicates (1/4 and 1/8 duplicates). A set of standards was assessed in parallel together with an internal control sample of known concentration. As a control for BCA measurement, we used a pork muscle homogenate at 2 mg/mL, and it was further used as an internal and inter-lab quality control for MRC assays.

After protein quantification, we recommend preparing aliquots with at least 500 µL of 2 mg/mL tissue homogenate, 200 µL of cell suspension or 100 µL of mitochondria-enriched suspension for further measurements of MRC. Samples should be immediately stored at $-80 \pm 5 \, ^\circ C$ in aliquots, if enzymatic assays cannot be performed within the same day to avoid extra freeze–thaw cycles.
DAY 3 (3 h)  
CIV, CII, CII+III, CS MRC ASSAY  

~50 mg  
Ice–cold tissue  
Immediate freezing at − 80°C  

~50 mg  
Ice–cold tissue  

~5 million cells in  
Ice–cold mannitol  
Immediate freezing at − 80°C  
Sonication twice  
5 sec 200 W  

Day 2 (5 h)  

Day 1 (15 min)  

Figure 1. Methodological procedure for sample handling and mitochondrial respiratory chain measurements.
(iv) MRC enzyme assessment (expected time: 6 h)

All enzymatic assays were performed using single-wavelength and temperature-controlled spectrophotometers, ideally with multi-cuvette carousel (for simultaneous multi-sample analysis) and controlled software analysis (for standard calculations). Although different temperature settings can be found in the literature [13–18], we measured all the MRC activities of human samples at physiological 37 °C. Temperature settings were compared with external calibrated temperature probes. When temperature-controlled devices (water bath and Peltier) showed variations up to 3 °C between nominal and actual temperature in cuvettes, variations were compensated to adjust actual cuvette temperature to 37 °C.

Table 2 summarizes the experimental conditions for MRC assays. Although we recommend performing all assays in one working day (about 6 h), if preferred, they can be performed in two separate days (3 h/day) with comparable results. For instance, we performed sample preparation, protein quantification and dilution into aliquots to a protein concentration of 2 mg/mL in day 1 (2 h procedure). Some aliquots were kept on ice for the subsequent determination of freeze–thaw sensitive MRC activities (day 1), and some aliquots were immediately frozen at −80 ± 5 °C to measure the remaining activities on day 2.

According to inter-laboratory and intra-laboratory results, enzyme assays with higher sensitivity to freeze–thaw cycles that should be performed on day 1 were quantified with complexes I, I + III and III, which showed lower activities in frozen homogenates (data not shown). Consequently, in this multicentric study, less sensitive complexes CII, CII + III, CIV and CS are recommended to be alternatively measured using frozen homogenates on day 2.

Since all MRC enzyme measurements should include an internal control sample run in parallel, all participating centers used frozen aliquots from a common pool of porcine skeletal muscle homogenate at 2 mg/mL, which was also used for protein measurement. MRC activities were assayed as described previously [15] (see Supporting information in Supplementary Materials), except for complex III and complex IV assays. In these cases, some modifications were introduced to improve both the reproducibility and linearity of these assays. As mentioned in the Reagent section, dithionite was changed to sodium borohydride as the source of electron donor for decylubiquinone reduction into decylubiquinol for complex III measurement [20], and detergent Tween 20 was added to facilitate membrane permeation in the case of complex IV assay. Additionally, a three-fold sample dilution was introduced for both CIII and CIV assays to improve the kinetic conditions [15], while maintaining the buffer concentration constant.

Although activity ranges and assay slopes were analyzed for each individual enzyme assay, we agreed to establish the previously recommended consensus analytic interval of 180 s for all MRC measurements [15], except for CI (60–180 s interval) and CI + III and CIII (0–90 s interval), which improved the reproducibility of the assays. Shorter time intervals are recommended for CIII-related assays to avoid non-linear kinetics due to the exhaustion of redox substrates. In all measurements, when kinetics of the reaction is not linear during the overall time interval (R value ≥ 0.975), the dilution of the sample is mandatory to prevent an underestimation of the potential enzymatic activity.
Table 2. Standardized experimental conditions for mitochondrial respiratory chain assays.

|          | CI      | CII     | CIII    | CIV     | CI + III | CII + III | CS       |
|----------|---------|---------|---------|---------|----------|-----------|----------|
| Wavelength (nm) | 340     | 600     | 550     | 550     | 550      | 550       | 412      |
| Buffer   | 50 mM KP pH 7.5 | 25 mM KP pH 7.5 | 25 mM KP pH 7.5 | 50 mM KP pH 7.0 | 50 mM KP pH 7.5 | 20 mM KP pH 7.5 | 100 mM Tris-HCl pH 8.1 |
| Substrates | 100 µM NADH | 20 mM Succinate | 75 µM Cytochrome C | 100 µM Reduced Cytochrome C | 200 µM NADH | 100 µM Cytochrome C | 20 mM Succinate |
|          | 100 µM DQ | 50 µM DCPIP | 0.1 mM EDTA, 0.025% Tween 20 | 0.5 mM KCN | 100 µM Cytochrome C | 100 µM Cytochrome C | 300 µM Acetyl-CoA |
|          | 100 µM DQH2 | 100 µM DQH2 | 3-fold diluted 20 µg protein | 3-fold diluted 40 µg protein | 40 µg protein | 40 µg protein | 100 µM DTNB |
|          | 100 µM DQ  | 100 µM DQ  | 500 µM Oxaloacetate | 500 µM Oxaloacetate | 500 µM Oxaloacetate | 500 µM Oxaloacetate | 500 µM Oxaloacetate |
| Other reagents | BSA 3.75 mg/mL | BSA 2 mg/mL | 0.1 mM EDTA | 1 mg/mL | 1 mM KCN | BSA 2 mg/mL | 0.1% Triton X-100 |
| Specific inhibitor | 12.5 µM Rotenone | 1 mM KCN | Aa 10 µg/mL | 12.5 µM Rotenone | 1 mM KCN |
| Muscle homogenate | 40 µg protein | 40 µg protein | 3-fold diluted 20 µg protein | 3-fold diluted 40 µg protein | 40 µg protein | 40 µg protein | 40 µg protein |
| Preincubation time | 5 min | 5 min | 5 min | 5 min | 5 min | 5 min | 5 min |
| Baseline reaction | - | 3 min | - | - | - | Control without sample | 4 min |
| Initiator of the reaction | 100 µM NADH | 100 µM DQ | 100 µM DQH2 | Sample | 200 µM NADH | 100 µM Cytochrome C | 500 µM Oxaloacetate |
| Total assay time(selected interval) | 3 min (consider 1–3) | 3 min (consider 0–3) | 3 min (consider 0–1.5) | 3 min (consider 0–3) | 3 min (consider 0–1.5) | 3 min (consider 0–3) | 4 min (consider 0–3) |
| ε (mmol·L⁻¹·cm⁻¹) | 6.2 | 19.2 | 18.5 | 18.5 | 18.5 | 18.5 | 13.6 |
| Calculation factor | 4032.3 | 1302.1 | 8108.1 | 4054.2 | 1351.4 | 1351.4 | 1838.2 |

The corresponding enzyme activity (nmol·min⁻¹·mg of protein⁻¹) is as follows: (Δabsorbance/min) × (Calculation factor indicated in Table 2). Aa, Antimycin A; Ac-CoA, Acetyl coenzyme A; ATP, Adenosine triphosphate; BCA, bicinchoninic acid; BSA, Bovine Serum Albumin; CI, complex I or NADH:ubiquinone oxidoreductase; CII, complex II or succinate:ubiquinone oxidoreductase; CIII, complex III or coenzyme Qcytochrome c oxidoreductase; CIV, complex IV or cytochrome c oxidase; CV, complex V or ATPase; CI + II, complex I + II or NADH:cytochrome c oxidoreductase; CII + III, complex II + III or succinate:ubiquinone-ubiquinol:cytochrome c oxidoreductase; COX, cytochrome c oxidase; CS, citrate synthase activity; DCPIP, 2,6-Dichlorophenolindophenol sodium salt hydrate; DQ, Decylubiquinone; DQH2, Decylubiquinol; DTNB, 5,5′-Dithiobis(2-nitrobenzoic acid); EDTA, Ethylenediaminetetraacetic acid disodium salt solution; EtOH, ethanol; HCl, Hydrogen chloride; KCN, Potassium cyanide; KP, Potassium phosphate buffer; PBMC, peripheral blood mononuclear cells; ROS, reactive oxygen species; OXS, oxidized solution; RS, reduced solution; SDH, succinate dehydrogenase; UCS, units of CS; β-Nicotinamide adenine dinucleotide; MB, mannitol buffer; MRC, Mitochondrial respiratory chain; PBMC, peripheral blood mononuclear cells; ROS, reactive oxygen species; OXS, oxidized solution; RS, reduced solution; SDH, succinate dehydrogenase; UCS, units of CS; β-Nicotinamide adenine dinucleotide; μg: Micrograms; min: Minute ε: Molar absorbance coefficient.
The Complex V measurement (ATP-proton synthase assay) is not included in most MRC assay protocols [15,16] because of insufficient reliability in frozen tissue or cells, due to negligible mitochondrial ATP hydrolysis in front of overall unspecific cell ATPase activity. Alternatively, this quantification can be performed with polarographic studies in oxygen consumption assays in fresh tissue or alive cells [21]. A spectrophotometric complex V measurement was also possible in mitochondria-enriched suspension from fresh tissue or live cells [22] or, in frozen samples, after the treatment of the cells with percoll and digitonin [23–25]. However, in our experience, the reproducibility of the results is usually suboptimal for diagnostic purposes. On the other hand, Blue Native Polyacrylamide gel electrophoresis (BN-PAGE) in combination with in-gel catalytic staining is a powerful tool for the diagnosis of oxidative phosphorylation defects, including complex V deficiency [26].

(v) CS enzyme quantification

The amount of mitochondria present in the samples is estimated by measuring the activity of the enzyme CS [17–19]. Although MRC activities can be expressed as specific values referred to as protein content (nmols/min·mg protein), they are usually normalized to CS activity in order to take into account the actual mitochondrial content.

(vi) Database, online work, quality controls and result analysis

The results of MRC enzyme activities of each participating center are systematically collected and updated online in cloud space where protocols, results and batches are recorded and shared among groups. Databases are routinely updated to gather reference control values, which include either the results of center-specific human samples or those of shared pork muscle aliquots used as common inter-group control samples (see Supplementary Table S2). The database was created for a dynamic, numeric, statistic and graphic analysis overview of the recruited results to evaluate center-specific deviations with respect to mean values or center-specific deviations over time (useful to detect batch-derived variations). Additionally, annual calibration samples are routinely analyzed and compared among participating centers to test inter-laboratory variability.

3. Results and Discussion

The present study provides data from seven independent centers summarizing all the experimental steps of MRC standardization using data from human muscle samples. The results of MRC enzymatic activities in human muscle homogenates after protocol standardization are shown in Table 3 and Figure 2, expressed as mean and standard deviation and include specific activities or relative values to CS. Table 4 summarizes the troubleshooting recommendations for different problems potentially arising during protocol set up. Table 5 shows the results of the standardization of MRC assays in other human samples (fibroblasts and PBMC), while internal quality controls can be found in Supplementary Table S2.

The results herein described are comparable to those obtained by the French laboratories [15], including CIII and CIV measurements where we had to introduce some technical modifications for optimal measurements. As shown in Table 3 and Figure 2, specific activities and, in particular, relative enzymatic activities to CS were similar after protocol standardization and achieved reference ranges comparable with the French laboratories. Importantly, inter-laboratory differences became smaller when enzymatic activities were related to CS to normalize MRC relative to mitochondrial extraction efficiency (see coefficient of variation and color distribution of Table 3, Table 5 and Supplementary Table S2). Additionally, the normalization of MRC enzyme activities to the mitochondrial content is a useful tool to correct potential increases in mitochondrial activities that may occur in some mitochondrial diseases to preserve mitochondrial function [1–3]. Consequently, in this study, we highly recommend relative MRC assessment to CS in order to minimize inter-laboratory variability [17–19].
The pathological threshold for biochemical mitochondrial disease diagnosis should be set after analyzing the maximal number of control muscle samples available. However, due to invasiveness of muscle biopsies, diagnostic centers usually use those obtained from patients as control samples, when potential pathological mitochondrial conditions have been ruled out. On the other hand, the analysis of previously confirmed pathological samples is also very helpful to validate healthy reference values.

**Figure 2.** Graphical comparison of data from Table 3 corresponding to mitochondrial respiratory chain enzymatic results of human muscle samples analyzed in five of the seven participating centers (affiliations 1 to 5) and results of three French groups (Medja et al. [15]). Two participating laboratories (affiliations 6 and 7) did not provide data because they focused their activity on animal and cell models. (A) Specific MRC enzymatic activities; (B) Relative MRC enzymatic activities to CS content.
Table 3. Mitochondrial respiratory chain enzymatic results of human muscle samples analyzed in five of the seven participating centers (affiliations 1 to 5) and comparison with respect to reports of three French groups (Medja et al. [15]). Two participating laboratories (affiliations 6 and 7) did not provide data because they focused their activity on animal and cell models.

| Complex | Activity | IBC U737 (n = 119) | HCL U722 (n = 29) | 12O U723 (n = 25) | VH U781 (n = 14) | UPO U729 (n = 78) | Paris Lab 1 (n = 89) | Angers Lab 2 (n = 39) | Caen Lab 2 (n = 26) |
|---------|----------|---------------------|-------------------|-------------------|-----------------|-------------------|---------------------|---------------------|---------------------|
| I       | Specific | 37.99 ± 14.86       | 25.09 ± 9.09      | 74.12 ± 19.95     | 27.20 ± 5.82    | 32.32 ± 11.33     | 42 ± 16              | 42 ± 8               | 56 ± 31              |
|         | Relative to CS | 0.23 ± 0.07       | 0.22 ± 0.04       | 0.37 ± 0.07       | 0.16 ± 0.03     | 0.21 ± 0.04       | 0.19 ± 0.05          | 0.19 ± 0.05          | 0.27 ± 0.06          |

| II      | Specific | 62.46 ± 22.54       | 40.80 ± 8.78      | 86.03 ± 17.34     | 50.37 ± 13.41   | 34.32 ± 9.03      | 61 ± 22              | 68 ± 20              | 79 ± 38              |
|         | Relative to CS | 0.08 ± 0.08       | 0.32 ± 0.13       | 0.43 ± 0.06       | 0.29 ± 0.03     | 0.20 ± 0.02       | 0.29 ± 0.07          | 0.27 ± 0.07          | 0.40 ± 0.11          |

| III     | Specific | 164.21 ± 46.29      | 129.77 ± 44.82    | 222.94 ± 54.77    | 101.44 ± 19.82  | 142.45 ± 43.90    | 166 ± 72             | 301 ± 77             | 252 ± 119            |
|         | Relative to CS | 0.92 ± 0.24       | 1.21 ± 0.20       | 1.18 ± 0.16       | 0.99 ± 0.14     | 0.95 ± 0.27       | 0.76 ± 0.25          | 1.21 ± 0.31          | 1.33 ± 0.46          |

| IV      | Specific | 180.15 ± 53.34      | 88.47 ± 31.63     | 273.31 ± 54.10    | 80.87 ± 33.15   | 132.09 ± 41.0     | 184 ± 64             | 210 ± 42             | 205 ± 98             |
|         | Relative to CS | 0.81 ± 0.28       | 0.72 ± 0.13       | 1.53 ± 0.16       | 0.43 ± 0.14     | 0.80 ± 0.12       | 0.90 ± 0.24          | 0.86 ± 0.21          | 1.02 ± 0.32          |

| I + III | Specific | 21.41 ± 12.20       | 15.61 ± 6.92      | 35.17 ± 6.80      | 16.22 ± 4.88    | 19.36 ± 5.62      | 32 ± 16              | NA                  | NA                  |
|         | Relative to CS | 0.13 ± 0.06       | 0.10 ± 0.03       | 0.30 ± 0.20       | 0.20 ± 0.14     | 0.12 ± 0.03       | 0.12 ± 0.03          | NA                  | NA                  |

| II + III| Specific | 36.33 ± 10.57       | 25.73 ± 5.53      | 40.03 ± 7.35      | 24.21 ± 2.75    | 31.08 ± 6.18      | 49 ± 16              | 48 ± 13              | 77 ± 46              |
|         | Relative to CS | 0.21 ± 0.08       | 0.24 ± 0.08       | 0.19 ± 0.03       | 0.12 ± 0.03     | 0.21 ± 0.04       | 0.21 ± 0.04          | NA                  | NA                  |

| CS      | Specific | 172.02 ± 47.6       | 121.48 ± 30.23    | 196.19 ± 38.20    | 191.55 ± 60.88  | 160.87 ± 27.02    | 220 ± 74             | 278 ± 52             | 202 ± 102            |

Results are expressed as mean ± 1 standard deviation in nmols-min⁻¹·mg of protein⁻¹ and Coefficient of Variation (CV). Participating centers: IBC, HCL, 12O, VH and UPO (affiliations 1–5). French laboratories (Medja et al., 2009 [15]): 1. La Salpêtrière hospital (Paris, France), 2. CHU d’Angers (Angers, France) and 3. CHU de Caen (Caen, France); I-IV: Enzymatic activities of MRC complexes I to IV; CS: Enzymatic activity of citrate synthase.
Table 4. Troubleshooting recommendations.

| Problem | Cause | Solution |
|---------|-------|----------|
| Low MRC enzymatic activities | Excessive homogenization deteriorates sample stability | Normalize by citrate synthase and, if possible, repeat homogenization |
| | Incorrect protein quantification with overestimation of real value | Normalize by citrate synthase and, if possible, repeat protein quantification |
| | Temperature of spectrophotometer is below 37 °C | Check temperature of the spectrophotometer |
| | Different wavelength than required for the assay | Check wavelength requirement of the specific assay |
| | Reaction medium or required reagent for the assay has been deteriorated | Check reagent storage: protection from light, cold storage, too long time since preparation |
| | Not enough sample has been added to the assay | Duplicate or triplicate sample amount |
| | Excessive sample has been added to the assay (usually reaction will not be linear) | Decrease by half or third sample amount |
| Low Complex I activity | NADH has been oxidized | Check macroscopic appearance of stored NADH (NADH should be dry and white) |
| | Inhibition is not efficient | Check proper Rotenone addition and mixture into the cuvette (appropriate handling and pipetting) |
| Low Complex II activity | Lack of electron acceptor (reaction product) | Check DCPIP expiration date |
| Low Complex III activity | Lack of electron donor (substrate product) | Check decylubiquinol expiration date |
| | Inhibition is not efficient | Check proper antimycin a addition into cuvette (appropriate handling and pipetting) |
| Low Complex IV activity | Lack of electron donor (substrate product) | Check if absorbance of reduced cytochrome c is still in the proper range (90–95% oxidized one) |
| Low Complex I + III activity | Inhibition is not efficient | Change of cytochrome c batch |
| Low citrate synthase | Reaction medium or required reagent for the assay has been deteriorated | Check acetyl coenzyme a, oxaloacetate and DTNB integrity |
| High MRC enzymatic activities | Incorrect protein quantification (below real value) increased calculations | Normalize by CS and, if possible, repeat protein quantification |

DCPIP: 2,6-Dichloroindophenol sodium salt hydrate; DTNB: 5,5′-Dithiobis (2-nitrobenzoic acid); NADH: β-Nicotinamide adenine dinucleotide; Complexes I-IV: Enzymatic activities of MRC complexes I to IV; CS: Enzymatic activity of citrate synthase; MRC: mitochondrial respiratory chain.

The reference interval is usually established as one or two standard deviations from the average reference value, encompassing the 84th to 95th percentile of the healthy population, in the case of normal distributed parameters. However, alternative statistical calculations are also used (maximum–minimum scores, reference interquartile range, etc.).
Table 5. Mitochondrial respiratory chain enzymatic results of control human fibroblasts and peripheral blood mononuclear cells (PBMC) in two participating centers compared to previous reports by French network [15].

| Complex | Activity | Fibroblasts | | | PBMC | |
|---------|----------|-------------|---|---|---|---|
|         |          | IBC U737 (n = 28) | French Group (n = 50) | HCL U722 (n = 11) | |
| I       | Specific | Mean ± SD | CV | Mean ± SD | CV | Mean ± SD | CV |
|         | Relative to CS | NA | NA | NA | NA | 28.99 ± 8.36 | 28.8 |
| II      | Specific | 29 ± 6 | 20.7 | 27 ± 8 | 29.6 | 19.42 ± 1.81 | 9.3 |
|         | Relative to CS | 0.64 ± 0.11 | 17.1 | 0.36 ± 0.10 | 27.8 | 0.85 ± 0.14 | 16.5 |
| III     | Specific | 36 ± 12 | 33.3 | 35 ± 17 | 30.9 | 28.04 ± 4.31 | 15.4 |
|         | Relative to CS | 0.78 ± 0.28 | 35.9 | 0.79 ± 0.25 | 31.6 | 1.37 ± 0.20 | 14.6 |
| IV      | Specific | 45 ± 12 | 26.6 | 83 ± 15 | 18.1 | 16.44 ± 3.04 | 18.5 |
|         | Relative to CS | 1.00 ± 0.15 | 15 | 1.12 ± 0.22 | 19.6 | 0.63 ± 0.11 | 17.5 |
| I + III | Specific | 28 ± 14 | 50 | 24 ± 7 | 29.2 | NA | NA |
|         | Relative to CS | 0.55 ± 0.17 | 30.9 | NA | NA | NA | NA |
| II + III| Specific | 16 ± 4 | 25 | 30 ± 7 | 23.3 | NA | NA |
|         | Relative to CS | 0.33 ± 0.1 | 30.3 | NA | NA | NA | NA |
| CS      | Specific | 51 ± 11 | 21.6 | 79 ± 18 | 22.8 | 24.30 ± 7.61 | 31.3 |

Results are expressed as mean ± 1 standard deviation in nmol·min⁻¹·mg protein⁻¹ and Coefficient of Variation (CV). IBC (U737 CIBERER): Sección de Errores Congénitos del Metabolismo (IBC), Servicio de Bioquímica y Genética Molecular, Hospital Clínic de Barcelona, IDIBAPS and CSIC, Barcelona, Spain; HCL (U722 CIBERER): Laboratorio de Investigación Muscular y Función Mitochondrial, Cellex-IDIBAPS, Facultad de Medicina-Universidad de Barcelona, Departamento de Medicina Interna-Hospital Clínic de Barcelona, Barcelona, Spain; All of them from the Centro de Investigación Biomédica en Red (CIBER), Sección de Enfermedades Raras (CIBERER); French laboratory: La Salpêtrière hospital (Paris, France); I–IV: Enzymatic activities of MRC complexes I to IV; CS: Enzymatic activity of citrate synthase; NA: Not available.

Regarding the source of variability for the reference ranges used in the different sites (see Table 3), we did not detect significant demographic differences in age and gender between institutions, except for one site (HCL U722), with an equal parity in males to females’ ratios (as the rest of centers) but a differential age of range onset (starting in adulthood vs. newborn inclusion for the rest of sites). The reason of this center for focusing on reference ranges extracted from adult individuals is that this site does not diagnose pediatric patients. Interestingly, this institution showed the lowest values of mitochondrial respiratory chain activities (Table 3). Whether aging was or not the causal reason for such differences is still a matter of doubt, since age stratification is not feasible due to reference ranges based on small cohort sample sizes. Remarkably, supporting age and site-specific control characteristics influence on variability, MRC divergence was smaller when the same common control pork sample was evaluated for the same sites (see Supplementary Table S2).

MRC enzyme deficiency may be suspected when enzyme activity is lower than this reference value, particularly if the patient shows clear symptoms of mitochondrial disease and additional evidence of mitochondrial dysfunction such as elevated mitochondrial content (CS activity), abnormal anatomopathological findings (either ragged-red fibbers or COX−/SDH+ cells) or genetic variations.

Of note, diagnostic thresholds depend on the source of samples analyzed, as well as reference values and the rate of false positive/negative values assumed. Sample analysis may vary, mainly, depending on size of the cohort, variable distribution (Gaussian or non-parametric) and composition (healthy individuals or both healthy individuals and patients), among others. The rate of sensitivity and specificity assumed (alpha and beta...
errors) will determine the risk of ascertainment bias in false/positive diagnosis. Thus, each center establishes the pathological threshold based on mean values plus one or two standard deviations (for parametric parameters) or median values and percentiles (for non-parametric parameters), depending on all these considerations [25]. Additionally, in the case of the evaluation of pediatric patients, it is advisable to set range values depending on the patient age due to MRC activity and mitochondrial content drift after the first stages of life [26].

In our experience of multicentric protocol implementation, the network for communication in-person, online, by-phone or electronic mail among the members of all participating centers was essential for the work-in team in terms of troubleshooting and result comparisons. Additionally, the daily update of our online cloud-space databases was useful for the following: (i) record comparable information of control ranges, either from human or reference samples; and (ii) detect site-specific deviations, variations over time and batch-dependent changes. The annual exchange of calibration samples was routinely performed to detect potential bias.

During the setup of MRC measurements, the comparison of our results with previously published data [15] was crucial to optimize our protocols. The aim of this manuscript is to help others with the same purpose.

One important source of variability affecting several MRC assays (complexes I + III, II + III and IV) was the cytochrome c reagent. Further research should be performed to normalize the basal redox balance of this commercial reagent to reduce derived batch-dependent variability.

Despite all the above-mentioned complexities, the standardization of protocols for the validation of MRC measurements is an urgent need for all laboratories studying MRC defects, especially in diagnostic centers. It is difficult to avoid epidemiologic, logistic or sample collection differences between sites, which reflects the complexity that diagnostic and research laboratories face on a daily basis with real world circuits. However, it is possible to minimize the source of experimental variability in the laboratory analyses with standardized and robust experimental protocols.

We strongly recommend setting up the herein reported protocols, as we found them to be reliable and sensitive, and they are specific methods for the study and diagnosis of mitochondrial dysfunction. These protocols are also recommended in the context of research settings, since they provide reliable methodological protocols for the measurement of MRC in humans not only in muscle biopsies but also in cell and animal models, setting the path for international standardization and the comparison of results in experimental networks or the scientific literature. In the case of MRC deficiency, the further association of mitochondrial defects with ROS production, proton leak, ATP decrease, heat imbalance, membrane potential disruption, dysfunctional mitophagy, altered calcium homeostasis or apoptosis may help to establish a link between organelle-to-cell dysfunction and disease.

4. Conclusions

1. Mitochondrial respiratory chain enzymatic assays are relevant analytical tools in research and diagnosis with high inter-laboratory variability.
2. Updated and functional standardized protocols, normality ranges and troubleshooting methods are herein provided to overcome the most common experimental challenges.
3. This Spanish multicentric study joins the previous French and Italian initiatives to encourage other countries to establish common international analytical standards.
4. Additional analyses of clinical, genetic and pathological measures should be performed to better understand the contribution of MRC defects to human disease.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antiox11040741/s1, Supplementary File: Supporting information; Table S1: Characteristics of the samples and individuals from the different sites of the study included as reference ranges (Tables 3 and 5); Table S2: Representative data of the control porcine sample.
Author Contributions: Conceptualization, L.G., G.G., M.A.M., E.G.-A., J.C.R.-A. and M.A.F.-M.; methodology, N.B., C.M., F.J.G.-G., A.B., C.C., A.B.C., C.G., E.L.-G., E.L., S.M., L.G., E.T., A.D., M.A.M., M.A.F.-M., E.R.-P., E.G.-A., J.C.R.-A. and G.G.; validation, N.B., C.M., F.J.G.-G., A.B., C.C., A.B.C., C.G., E.L.-G., E.L., S.M., L.G., E.T., A.D., M.A.M., M.A.F.-M., E.R.-P., E.G.-A., J.C.R.-A. and G.G.; writing—original draft preparation, J.C.R.-A., E.G.-A. and G.G.; writing—review and editing, J.C.R.-A. and G.G.; supervision, J.C.R.-A. and G.G. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Instituto de Salud Carlos III (ISCIII), grants FIS PI17/00021, PI17/00359, PI18/00498, PI18/00451, PI18/01374, PI19/01772, PI20/00541, PI21/00229, PI21/00381 and PI21/00935 (ISCIII-FEDER “Cofinanciado por la Unión Europea”), Fundación Privada Cellex, Junta de Andalucía (UPO-1262247) and Ministerio de Ciencia e Innovación (MCINN) grant PID2019-110320RB-I00. All participant centers are integrated in the Centro de Investigación Biomédica en Red (CIBER), Sección de Enfermedades Raras (CIBERER, an initiative of ISCIII), which is the founder of this present methodological study.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of each institution: IBC U737 (C000128), HCL U722 (HC82017/0808), 120 U723 (CEl:18/487), VH U701 (PRIR)63/2016) and UPO U729 (C.I. 2768-N-21).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All data used to support the findings of this study are included within the article.

Acknowledgments: We are thankful to Anne Lombès and Claude Jardel for methodological assistance in French protocol establishment and accepting the first author of this work (N.B.) for a short stay in their laboratory (Laboratoire de Biochimie Métabolique in Paris, France). We are in debt to our laboratory staff for setting up experimental procedures (Rosana Hernandez, Sonia Moliner, Ester Ramón, Elena Sellés and Paz Briones). We are grateful to Pilar del Hoyo-Gordillo for her technical support. We also are grateful to Begoña Bretón and Rosana Hernández Sierra. We sincerely appreciate the disinterested participation of the volunteers for biological sample donation.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Mari, M.; Colell, A. Mitochondrial Oxidative and Nitrosative Stress as a Therapeutic Target in Diseases. Antioxidants 2021, 10, 314. [CrossRef] [PubMed]
2. Ježek, P. Mitochondrial Redox Regulations and Redox Biology of Mitochondria. Antioxidants 2021, 10, 1921. [CrossRef]
3. Vafai, S.B.; Mootha, V.K. Mitochondrial disorders as windows into an ancient organelle. Nature 2012, 491, 374–383. [CrossRef] [PubMed]
4. Vuda, M.; Kamath, A. Drug induced mitochondrial dysfunction: Mechanisms and adverse clinical consequences. Mitochondrion 2016, 31, 63–74. [CrossRef]
5. Munnich, A.; de Lonlay, P.; Ärttö, A.; Rustin, P. Mitochondrial disorders. Bull. Acad. Natl. Med. 2009, 193, 19–41, discussion 41–43. [PubMed]
6. Wibom, R.; Hagenfeldt, L.; von Döbeln, U. Measurement of ATP production and respiratory chain enzyme activities in mitochondria isolated from small muscle biopsy samples. Anal. Biochem. 2002, 311, 139–151. [CrossRef]
7. Cossarizza, A.; Ferraresi, R.; Troiano, L.; Roat, E.; Gibellini, L.; Bertonecelli, L.; Nasi, M.; Pinti, M. Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry. Nat. Protoc. 2009, 4, 1790–1797. [CrossRef] [PubMed]
8. Li, Z.; Graham, B.H. Measurement of Mitochondrial Oxygen Consumption Using a Clark Electrode. Methods Mol. Biol. 2011, 837, 63–72. [CrossRef]
9. Troiano, L.; Ferraresi, R.; Lugli, E.; Nemes, E.; Roat, E.; Nasi, M.; Pinti, M.; Cossarizza, A. Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat. Protoc. 2007, 2, 2719–2727. [CrossRef] [PubMed]
10. Pesta, D.; Gnaiger, E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol. Biol. 2012, 810, 25–58. [PubMed]
11. Acín-Perez, R.; Silva, P.F.; Peleato, M.L.; Pérez-Martos, A.; Enriquez, J.A. Respiratory Active Mitochondrial Supercomplexes. Mol. Cell 2008, 32, 529–539. [CrossRef]
12. Buján, N.; Arias, A.; Montero, R.; García-Villoria, J.; Lissens, W.; Seneca, S.; Espinós, C.; Navas, P.; De Meirleir, L.; Artuch, R.; et al. Characterization of CoQ10 biosynthesis in fibroblasts of patients with primary and secondary CoQ10 deficiency. *J. Inherit. Metab. Dis.* 2013, 37, 53–62. [CrossRef] [PubMed]

13. Casademont, J.; Perea, M.; López, S.; Beato, A.; Miró, O.; Cardellach, F. Enzymatic diagnosis of oxidative phosphorylation defects on muscle biopsy: Better on tissue homogenate or on a mitochondria-enriched suspension? *Med. Sci. Monit.* 2004, 10, CS49–CS53. [PubMed]

14. Gellerich, F.N.; Mayr, J.A.; Reuter, S.; Sperl, W.; Zierz, S. The problem of interlab variation in methods for mitochondrial disease diagnosis: Enzymatic measurement of respiratory chain complexes. *Mitochondrion* 2004, 4, 427–439. [CrossRef]

15. Medja, F.; Allouche, S.; Frachon, P.; Jardel, C.; Malgat, M.; Mousson de Camaret, B.; Slama, A.; Lunardi, J.; Mazat, J.P.; Lombès, A. Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis. *Mitochondrion* 2009, 9, 331–339. [CrossRef] [PubMed]

16. Spinazzi, M.; Casarin, A.; Pertegato, V.; Salviali, L.; Angelini, C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. *Nat. Protoc.* 2012, 7, 1235–1246. [CrossRef] [PubMed]

17. Barrientos, A. In vivo and in organello assessment of OXPHOS activities. *Methods* 2002, 26, 307–316. [CrossRef]

18. Rustin, P.; Chretien, D.; Bourgeron, T.; Gérard, B.; Rotig, A.; Saudubray, J.; Munnich, A. Biochemical and molecular investigations in respiratory chain deficiencies. *Clin. Chim. Acta* 1994, 228, 35–51. [CrossRef]

19. Pallotti, F.; Lenaz, G. Chapter 1 Isolation and subfractionation of mitochondria from animal cells and tissue culture lines. *Methods Cell Biol.* 2001, 65, 1–35. [CrossRef] [PubMed]

20. Rice, J.E.; Lindsay, J.G. Chapter 4: Subcellular fractionation of mitochondria. In *Subcellular Fractionation: A practical Approach*, 1st ed.; Graham, J.M., Rickwood, D., Eds.; Oxford University Press: Oxford, UK, 1997; pp. 107–142.

21. Gnaiger, E. Polarographic oxygen sensors, the oxygraph, and high-resolution respirometry to assess mitochondrial function. In *Drug-Induced Mitochondrial Dysfunction*, 1st ed.; Dykens, J., Will, Y., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2008; Volume 12, pp. 327–352.

22. Miró, O.; Jarreta, D.; Casademont, J.; Barrientos, A.; Rodríguez, B.; Gómez, M.; Nunes, V.; Urbano-Márquez, A.; Cardellach, F. Absence of mitochondrial dysfunction in polymyalgia rheumatica. Evidence based on a simultaneous molecular and biochemical approach. *Scand. J. Rheumatol.* 1999, 28, 319–323. [CrossRef] [PubMed]

23. Chretien, D.; Bénit, P.; Chol, M.; Lebon, S.; Rötig, A.; Munnich, A.; Rustin, P. Assay of mitochondrial respiratory chain complex I in human lymphocytes and cultured skin fibroblasts. *Biochem. Biophys. Res. Commun.* 2003, 301, 222–224. [CrossRef]

24. Casademont, J.; Garrabou, G.; Miró, O.; López, S.; Pors, A.; Bernardo, M.; Cardellach, F. Neuroleptic treatment effect on mitochondrial electron transport chain: Peripheral blood mononuclear cells analysis in psychotic patients. *J. Clin. Psychopharmacol.* 2007, 27, 284–288. [CrossRef] [PubMed]

25. Queraltó, J.M.; Antoja, F.; Cortés, M.; Doménech, M.V.; Fuentes, J.; Llagostera, M.J.; Llangostera, M.; Ramón, F.; Rojo, I. Bases estadísticas de la teoría de valores de referencia. *Rev. Soc. Esp. Quim. Clin.* 1983, 2, 95–105.

26. Bereiter-Hahn, J. Mitochondrial Dynamics in Aging and Disease. *Prog. Mol. Biol. Transl. Sci.* 2014, 127, 93–131. [CrossRef] [PubMed]